ArticleImmunology and cell biology2012
Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response.
Article in Immunology and cell biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Deficiency of SR-B1 reduced the tumor load of colitis-induced or APCCancer medicine · 2023Article
- CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine.Frontiers in immunology · 2023Article
- Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.Cancer research · 2021Article
- Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.Pharmaceutics · 2021Review
- Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity.Journal for immunotherapy of cancer · 2021Article
- Electrical Stimulation for Immune Modulation in Cancer Treatments.Frontiers in bioengineering and biotechnology · 2021Review
- Phagocytosis-Inflammation Crosstalk in Sepsis: New Avenues for Therapeutic Intervention.Shock (Augusta, Ga.) · 2020Review
- Immunometabolism: A new target for improving cancer immunotherapy.Advances in cancer research · 2019Review
- Understanding molecular interactions between scavenger receptor A and its natural product inhibitors through molecular modeling studies.Journal of molecular graphics & modelling · 2017Article
- IGFBP7 Deletion Promotes Hepatocellular Carcinoma.Cancer research · 2017Article
- Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.Bioorganic & medicinal chemistry letters · 2017Article
- Melanoma exosomes enable tumor tolerance in lymph nodes.Medical hypotheses · 2016Article
- Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Clinical immunology (Orlando, Fla.) · 2015Review
- Small molecule inhibits activity of scavenger receptor A: Lead identification and preliminary studies.Bioorganic & medicinal chemistry letters · 2015Article
- Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B.BMC immunology · 2015Article
- Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.Advances in cancer research · 2015Review
- Article
- Antigen-specific vaccines for cancer treatment.Human vaccines & immunotherapeutics · 2014Review
- High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Given the primary expression of scavenger receptor A (SRA) or CD204 on antigen-presenting cells, we investigate the immunoregulatory activities of SRA/CD204 in the context of cross-presentation of cell-associated antigen and the immunogenicity of dying tumor cells. Immunization with dying prostate cancer cells results in profoundly increased control of subsequently inoculated tumors in SRA/CD204 knockout mice. Using OVA-expressing RM1 prostate tumor line (RM1-OVA), we show for the first time that SRA absence greatly enhances dendritic cells (DCs)-mediated cross-presentation of OVA antigen derived from dying RM1 cells. While the phagocytic ability of DCs is not significantly impacted by the lack of SRA/CD204, DCs deficient in SRA/CD204 display increased expression of inflammatory cytokines and chemokines, as well as co-stimulatory molecules upon interaction with dying RM1 cells, implicating a suppressive regulation of the functional activation of DCs by SRA/CD204. Further, SRA/CD204-deficient DCs pulsed with dying RM1-OVA cells are more effective than wild-type counterparts in priming antigen-specific T-cell responses, resulting in improved control of RM1 tumor growth in both prophylactic and therapeutic settings. Our findings suggest that the increased immunogenicity of dying tumor cells in SRA/CD204 knockout mice is attributed to the altered functions of DCs in the absence of SRA/CD204, which underscores the important role of SRA/CD204 in host immune homeostasis. Selective downregulation or blockade of this immunoregulatory molecule may lead to enhanced potency of DC-based vaccines capable of breaking immune tolerance against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.